| 59.69 1.19 (2.03%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 71.68  |
1-year : | 83.72 |
| Resists | First : | 61.36 |
Second : | 71.68 |
| Pivot price | 56.78 |
|||
| Supports | First : | 54.85 |
Second : | 50.81 |
| MAs | MA(5) : | 57.95 |
MA(20) : | 56.27 |
| MA(100) : | 60.74  |
MA(250) : | 53.32 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 77.5 |
D(3) : | 74.3 |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 110.25 | Low : | 25.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CYTK ] has closed above the upper band by 10.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 61.43 - 61.66 | 61.66 - 61.93 |
| Low: | 57.95 - 58.2 | 58.2 - 58.48 |
| Close: | 59.22 - 59.63 | 59.63 - 60.09 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Fri, 26 Jul 2024
US Bancorp DE Acquires 2,265 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Thu, 25 Jul 2024
Cytokinetics to Announce Second Quarter Results on August 8, 2024 - GlobeNewswire
Thu, 25 Jul 2024
Cytokinetics to Announce Second Quarter Results on August 8, 2024 - StockTitan
Thu, 25 Jul 2024
Vanguard Group Inc. Has $700.90 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Thu, 25 Jul 2024
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Thu, 25 Jul 2024
Vanguard Group Inc. Sells 1,019,813 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 1.0429e+008 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 16,420 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.8559e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -15 % |
| Return on Assets (ttm) | 117.9 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 3.75e+006 % |
| Gross Profit (p.s.) | -109.2 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -422 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.9 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.85 |
| Dividend | 0 |
| Forward Dividend | 1.738e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|